Skip to main content

Table 3 Multivariate analysis of prognostic factors for OS and PFS of patients with DLBCL

From: Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study

Variate

OS

PFS

HR

95% CI

P

HR

95% CI

P

Age

1.38

1.69–9.40

< 0.01

0.39

0.87–2.51

0.15

Clinical stage

− 0.39

0.22–2.06

0.57

0.69

1.23–3.23

0.01

B symptoms

− 0.93

0.12–1.35

0.63

0.45

0.97–2.56

0.07

Spleen involvement

− 0.05

0.24–3.87

0.95

0.34

0.74–2.67

0.30

IPI

1.01

0.59–12.70

0.20

0.02

0.51–2.04

0.96

LDH

0.29

0.49–3.67

0.57

0.24

0.76–2.15

0.35

β2-MG

0.02

0.33–3.18

0.98

  

Rituximab

− 0.13

0.34–2.26

0.80

  

CR after first-line chemotherapy

− 1.54

0.09–0.49

< 0.01

− 0.24

0.48–1.27

0.33

PD-L1 expression in tumor cells

1.40

1.61–10.23

< 0.01

0.46

1.00–2.51

0.05

  1. IPI international prognostic index, LDH lactate dehydrogenase, β2-MG β2-microglobulin, CR complete remission, PD-L1 programmed cell death ligand 1, not included